Connoya Biomedical Technology

Keymed Biosciences (also known as Connoya) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative biological therapies for autoimmune and oncology indications. The company's lead candidate, Stapokibart (CM310), is a high-affinity monoclonal antibody targeting the IL-4Rα subunit, currently in late-stage development for atopic dermatitis and asthma. Keymed utilizes proprietary platforms like nAIB and Trimer-Body to develop a diverse pipeline of bispecific antibodies and antibody-drug conjugates. Headquartered in Chengdu with R&D facilities in Suzhou, the company is listed on the Hong Kong Stock Exchange and maintains strategic partnerships with global firms like AstraZeneca. The company possesses fully integrated capabilities from drug discovery to commercial-scale GMP manufacturing.